Facebook Live 003: New Treatments in Pipeline
Facebook LIVE 003:
Join us for our third Facebook Live
[May 18 at 10:30 am PST]
Facebook LIVE is a new feature for our academy students. Join us for our 3rd Facebook Live session with Dr. Harvinder Singh.
This session is dedicated to the discussion of the following three potential medications in the pipeline:
(1) Xanomeline-Trospium Chloride (KarXT) for Schizophrenia:
- Mechanism of Action How to Dose?
- EMERGENT-3 trial results
- Common Side Effects
(2) Subcutaneous Olanzapine Extended-Release Injection (TEV-‘749):
- Efficacy results from Phase 3 SOLARIS trial.
- Does this medication have Post-Injection Delirium/Sedation Syndrome?
(3) Liafensine for Treatment-Resistant Depression:
- Mechanism of Action.
- Results from Biomarker Guided Phase 2b Clinical Trial (ENLIGHTEN)
Here is one slide from this presentation explaining the:
Likely Mechanism of Action for karXT
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
© 2024 All Rights Reserved.
